Stryker Co. (NYSE:SYK) Shares Sold by Ramsay Stattman Vela & Price Inc.

Ramsay Stattman Vela & Price Inc. lowered its holdings in Stryker Co. (NYSE:SYK) by 1.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,077 shares of the medical technology company’s stock after selling 528 shares during the period. Stryker makes up 3.2% of Ramsay Stattman Vela & Price Inc.’s portfolio, making the stock its 6th biggest position. Ramsay Stattman Vela & Price Inc.’s holdings in Stryker were worth $15,595,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Farmers & Merchants Trust Co of Chambersburg PA increased its position in shares of Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares in the last quarter. Quarry LP acquired a new stake in Stryker during the 1st quarter valued at $27,000. Freedom Wealth Alliance LLC acquired a new stake in Stryker during the 4th quarter valued at $26,000. HBC Financial Services PLLC acquired a new stake in Stryker during the 4th quarter valued at $37,000. Finally, Bourgeon Capital Management LLC acquired a new stake in Stryker during the 4th quarter valued at $37,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares in the company, valued at approximately $4,856,522. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at approximately $1,317,414. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now owns 14,242 shares in the company, valued at $4,856,522. The disclosure for this sale can be found here. Insiders have sold a total of 212,109 shares of company stock worth $72,845,768 in the last ninety days. 5.90% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on SYK. Citigroup raised their price target on shares of Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a report on Wednesday, January 31st. Royal Bank of Canada raised their price objective on shares of Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. Roth Mkm raised their price objective on shares of Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and raised their price objective for the stock from $315.00 to $360.00 in a report on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $340.45.

Stryker Stock Performance

Shares of Stryker stock traded down $2.02 during trading hours on Friday, reaching $325.43. The company’s stock had a trading volume of 1,884,151 shares, compared to its average volume of 959,865. The company’s 50 day simple moving average is $350.01 and its 200 day simple moving average is $312.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The stock has a market cap of $123.82 billion, a P/E ratio of 39.45, a price-to-earnings-growth ratio of 2.62 and a beta of 0.89.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. During the same period last year, the firm posted $3.00 EPS. As a group, analysts expect that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 annualized dividend and a yield of 0.98%. Stryker’s dividend payout ratio is presently 38.79%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.